Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Cash & Current Investments (2016 - 2025)

Assembly Biosciences has reported Cash & Current Investments over the past 12 years, most recently at $248.1 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 121.37% year-over-year to $248.1 million; the TTM value through Dec 2025 reached $248.1 million, up 121.37%, while the annual FY2025 figure was $248.1 million, 121.37% up from the prior year.
  • Cash & Current Investments for Q4 2025 was $248.1 million at Assembly Biosciences, up from $232.6 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $248.1 million in Q4 2025 and troughed at $46.2 million in Q3 2023.
  • A 5-year average of $128.3 million and a median of $112.5 million in 2024 define the central range for Cash & Current Investments.
  • Biggest five-year swings in Cash & Current Investments: plummeted 57.47% in 2023 and later surged 144.92% in 2025.
  • Year by year, Cash & Current Investments stood at $146.6 million in 2021, then plummeted by 37.52% to $91.6 million in 2022, then surged by 42.18% to $130.2 million in 2023, then decreased by 13.95% to $112.1 million in 2024, then soared by 121.37% to $248.1 million in 2025.
  • Business Quant data shows Cash & Current Investments for ASMB at $248.1 million in Q4 2025, $232.6 million in Q3 2025, and $75.0 million in Q2 2025.